CH EPL (R5)
1.0.1 - trial-use
CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions
The European Medicines Agency (EMA) is the regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU). It coordinates the assessment and approval of medicinal products, supports pharmacovigilance activities, and works with EU Member States, national competent authorities, and stakeholders to ensure medicines are safe, effective, and of high quality. EMA’s work also facilitates harmonised regulatory practices across the EU/EEA.
EMA’s remit includes the implementation of international regulatory standards and data interoperability frameworks that underpin modern regulatory submissions and cross-border data exchange.
The Identification of Medicinal Products (IDMP) standards are a suite of ISO norms that define data elements and structures for uniquely identifying medicinal products, substances, dosage forms, units, and routes of administration. This set of standards enhances consistency, interoperability, and data quality in regulatory systems worldwide.
In the European Union, the use of IDMP standards is mandated by law:
ISO 11238, 11239, 11240, 11615, 11616) for the exchange and communication of medicinal product information across the EU.This ensures consistent and interoperable use of terminology, format, and standards among Member States, marketing authorisation holders (MAHs), and the EMA.
Official text (EUR-Lex):
🔗 Commission Implementing Regulation (EU) No 520/2012 – https://eur-lex.europa.eu/eli/reg_impl/2012/520/oj
To operationalise the legal requirements, EMA has developed a comprehensive IDMP Implementation Guide (EU IG) that defines how the ISO IDMP standards should be implemented in practice within the EU. This guide:
The Implementation Guide is periodically updated and serves as the authoritative reference for EMA’s IDMP rollout strategy.
To support machine‑readable regulatory data exchange, EMA has adopted FHIR (Fast Healthcare Interoperability Resources) as the data standard for its Product Management Service (PMS) API.
🔗 https://pms.ema.europa.eu/fhir/ig/
This FHIR‑based Implementation Guide:
The adoption of FHIR modernises regulatory data exchange, replacing legacy formats such as the eXtended EudraVigilance Product Report Message (XEVPRM) with a standards‑based API.
To implement IDMP effectively in Europe, EMA has developed the SPOR programme—a phased master‑data initiative that harmonises essential regulatory information and supports FHIR‑based exchange.
The SPOR initiative covers four master‑data domains used throughout the lifecycle of medicinal products:
🔗 Substance Master Data – https://spor.ema.europa.eu/smswi/#/
🔗 Product & Substance Management – https://spor.ema.europa.eu/pmswi/#/
🔗 Organisation Data Overview – https://spor.ema.europa.eu/omswi/#/.
🔗 Referential Data – https://spor.ema.europa.eu/rmswi/#/.